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Abstract 
Objective: The present review evaluates interventions that have been designed to improve understanding of the 
complex risk-benefit profiles of disease-modifying drugs (DMDs) in patients with Multiple Sclerosis (MS). 
Methods: A systematic search conducted using PubMed, Embase, Google Scholar and PsycINFO identified 15 studies. 
Interventions which provided treatment information were present across a range of study designs. A narrative synthesis 
was conducted due to heterogeneity of research findings.  
Results: Interventions providing treatment information ranged from comprehensive education programmes to booklets 
of a few pages. MS patients favoured the interventions they received. Understanding of overall treatment information 
and treatment risks specifically, generally improved following interventions. Yet overestimation of treatment benefits 
persisted. There was no conclusive effect on DMD decisions. No superior intervention was identified. 
Conclusion: Interventions designed to improve understanding of DMD risk and benefit information are moderately 
successful. 
Practice implications: Additional support provided to MS patients beyond routine healthcare can generally improve 
understanding of the complex risk-benefit profiles of DMDs. Future interventions need to ensure that patients with 
symptoms that may confound understanding can also benefit from this additional information. 
Keywords 
Multiple Sclerosis; disease-modifying drugs; evidence-based patient information; risks; benefits; understanding; 
intervention; systematic review 
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1. Introduction  
Multiple Sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, which progresses at different 
rates between individuals [1]. MS patients experience a range of symptoms, including depression [2–4], anxiety [2,5], 
fatigue [3,6] and cognitive impairments [5,7,8], which likely confounds patients’ general understanding and ability to 
recall important information. This could be problematic for MS patients when deciding a course of treatment.  
The treatments currently available to MS patients are disease-modifying drugs (DMDs). Although DMDs do not target 
symptoms of MS, they can potentially reduce the number of relapses and delay progression of disease [9]. Yet the rate 
at which these benefits occur vary between DMDs and can even vary within individuals treated with the same 
medication. In general, MS patients are initially offered treatments with long-term safety profiles and limited adverse 
risks, but these are only moderately successful [10]. These treatments are also known as first-line DMDs. More 
aggressive treatments may be considered when initial therapies are not effective. DMDs at this stage offer higher 
benefits but potentially adverse effects, including Leukaemia, Cardiotoxicity, and Progressive Multifocal 
Leukoencephalopathy (PML) [9–13]. MS patients are therefore faced with complex risk-benefit profiles of DMDs when 
deciding on the best course of treatment. 
An understanding of the risks and benefits of treatments is one of the many components required for an effective 
shared treatment decision. Shared decision-making is a highly recommended concept in patient-centered healthcare 
and refers to the mutual exchange of information between patients and health professionals during decision-making, 
such as decisions made about the most suitable treatment course [14,15]. This approach is particularly suited to chronic 
conditions such as MS, where the risk-benefit profiles of treatments are complex and need to be effectively 
communicated in order to inform and engage patients in treatment decisions [16,17]. Thus, it is reasonable to expect 
that improving MS patients’ understanding of complex risk-benefit profiles of DMDs can have an impact on treatment 
decision-making. 
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To facilitate understanding, patients should ideally be presented with treatment options and treatment risk-benefit 
profiles in a clear and coherent manner [14,18]. Yet DMD information provided to MS patients during routine healthcare 
is not always clear or coherent [19–21]. This may explain why many MS patients actively seek DMD information 
elsewhere [22,23]. This external information may not be accurate or up-to-date, which could lead to further 
misunderstanding of treatment information. Interventions have been designed to provide information about the risks 
and benefits of DMDs that patients may seek beyond routine healthcare. Although such interventions aim to provide 
accurate information about DMD risks and benefits, it is also important to consider the way this information is 
presented. This is because understanding of treatment risks and benefits can be influenced by particular graphical [24–
26] or numerical formats [27–29], the framing of information [30–32] and how comparisons of risks and benefits are 
communicated [33–35]. Thus, an ideal intervention will give patients unbiased and accurate treatment information using 
effective presentation methods in order to optimise the understanding of DMD risks and benefits, and consequently 
result in informed treatment decisions.  
Köpke, Solari, Khan, Heesen and Giordono [36] recently reviewed 10 interventions designed to aid patient 
understanding of MS related information, which includes two interventions that specifically provided information about 
the risks and benefits of DMDs. Although all interventions reviewed were different in many respects, understanding of 
the disease generally improved post-intervention. Despite this improvement there was no conclusive effect on decision-
making. This review, however, was limited to randomised controlled trials only, which does not allow for a 
comprehensive evaluation of all interventions that provide MS information beyond routine healthcare, particularly 
information on the risks and benefits of DMDs [36]. 
To the best of our knowledge, the present systematic review is the first comprehensive evaluation of interventions 
primarily designed to improve understanding of risks and benefits of DMDs for MS patients. This review will also explore 
the effects of these interventions on patients’ treatment decisions. 
2. Methods 
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The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were used as 
guidelines for the presentation of this review [37]. A protocol for the present review was not previously published or 
registered. 
2.1. Systematic literature search 
The systematic literature search was conducted in November 2016 using PubMed, Embase, Google Scholar and 
PsycINFO. Uniform search terms were developed and used with all databases (see table 1). 
2.2 Eligibility criteria 
The inclusion criteria for the studies in the present review were peer-reviewed studies in English, with human adults and 
with patients of any clinical subtype of MS. No date restriction was applied. Studies were not limited to any particular 
study design. No restrictions were placed on the type of control group. Studies were required to have interventions 
about either real DMD information or information about fictitious treatments which would eventually support 
understanding of DMD information. Interventions were defined as any additional strategy or decision-aid which 
provided treatment information beyond that given during routine healthcare. Studies with some evaluation of these 
interventions were retained. 
Studies were excluded if they evaluated educational interventions for complementary medicines or medications for the 
management of MS symptoms. Studies assessing patients’ understanding for disease diagnosis or prognosis were not 
eligible for inclusion. Studies without any form of educational intervention, with interventions based on other aspects of 
MS such as cognition or self-management, interventions aimed primarily at health professionals, an intervention 
protocol for an upcoming study with no existing data, or interventions not exclusive to patients with MS, were also 
excluded from the review. 
All titles and abstracts were screened. Studies that were considered relevant from additional reference checking were 
also included. At this stage, 96 studies were considered for eligibility and full texts were subsequently accessed (see 
figure 1). 
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2.3. Data extraction 
Data extraction forms were created to extract relevant information from the full texts, and assess their eligibility into the 
final review. Extraction was initially carried out by one reviewer (GR) and was verified by another (DL).  Any 
discrepancies were resolved by discussion. Following data extraction, 81 studies were excluded from the final review in 
line with the exclusion criteria (see figure 1). 
Baseline characteristics of participants were extracted from the 15 shortlisted studies, comprising (where reported) age, 
type of MS, disease duration, time since diagnosis and current DMD. Study design and methodology was recorded. 
Information about the interventions was further extracted, including the content, length, presentation methods and any 
additional details of how the interventions were conducted. 
The impact of the interventions on either understanding of treatment information overall or understanding of treatment 
risks and benefits specifically was also extracted in the present review and incorporates data from self-report and 
objective measures. Patient’s feedback on the interventions was also retained. Relevant data for the present review was 
obtained from numerical information in texts, tables and graphs, and statistical analysis. 
2.4. Quality assessment 
Quality of publications was independently examined by two reviewers (GR and DL) using the Effective Public Health 
Practice Project (EPHPP) quality assessment tool for quantitative studies [38]. This particular tool was chosen because it 
can evaluate all types of quantitative studies in the health care setting [39], has high inter-rater reliability [39] and is 
often considered ideal for systematic reviews [40]. As per the tool, the final quality rating was derived from the rating of 
six measures: selection bias, study design, confounders, blinding, data collection methods, and withdrawals or drop-outs 
(see table 2). 
Quality was further assessed for educational interventions within the studies, based on their reporting of criteria for 
evidence-based patient information. Eight different criteria were chosen and adapted from Bunge and colleagues [18], 
depending on the extent of evidence and relevance to both simple and complex educational interventions (see table 3).  
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3. Results 
3.1 Study design and participant demographics (table 4) 
Fifteen studies were shortlisted in the review, and comprised interventions which were primarily designed to improve 
understanding of DMD risk and benefit information in MS patients. Four studies in this review evaluated interventions 
using a randomised controlled procedure [41–44]. A type of control group was present in seven studies [41,42,44–48] 
and baseline scores prior to the intervention were recorded by ten studies [42,43,47–53]. 
Five of the 15 studies were considered to be of a high quality [41–43,48,49], with three studies deemed weaker in 
quality [44,50,54] (see table 2). Four of the 15 studies had interventions that fulfilled or reported at least 4 of the 8 
criteria for evidence-based patient information. The most commonly reported criteria in the interventions were the use 
of comprehension enhancing tools, involvement of patients in the development process and inclusion of numerical data 
(see table 3). 
A total of 2552 MS patients were included across 15 studies and had a range of MS disease subtypes, comprising: 
79(3.1%) CIS patients, 1064 (41.7%) RRMS patients, 214 (8.4%) PPMS patients and 391 (15.3%) SPMS patients. The 
remaining MS patients had unclear or unreported MS disease subtype (31.5%). The mean age of patients was 43.1 years 
(range: 37– 50). One study did not allow for calculation of mean age [49] and two studies only presented median or 
mode values for age [46,52]. Two studies also included 105 non-MS patients, with a mean age of 43.5 years [45,54].  
Nine studies reported patients’ disease duration from initial MS symptoms [42–44,46,47,50,53–55], with an average of 
9.2 years. Five studies reported time since MS diagnosis [41,42,48,51,52], with an average of 5.8 years. 
Only one included study reported patients’ objective cognitive status [45]. Patients were assessed on the California 
Verbal Learning Test-II (CVLT-II), Wisconsin Card Sorting Test-64 (WCST) and the Digit Span subtest from Wechsler Adult 
Intelligence Scale. MS patients were considered to be cognitively impaired if they scored below the 5th percentile of at 
least one cognitive measure [45]. 
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A total of 1384 (54.2%) MS patients had taken disease-modifying drugs during the course of their disease and 188 (7.4%) 
MS patients had not taken a DMD. The remaining studies did not specify DMD status (980 MS patients, (38.4%)). Of 
studies reporting MS patients’ current DMD, 273 patients were on the first-line treatment interferon-beta  [42,49,51], 
and the remaining patients were taking second-line treatments, with 53 patients on Mitoxantrone [50], 173 patients on 
Natalizumab [46,55] and 98 patients on Fingolimod [52]. In majority of these studies, DMD status was known by treating 
physicians or researchers involved with the study [46,47,49–52,55] . 
3.2 Intervention characteristics (table 5) 
Intervention type. The majority of interventions contained a booklet or leaflet for MS patients [41–
44,46,48,50,51,53,55]. These leaflets ranged from providing comprehensive information (120 pages, [41,48]; 57 pages 
[42]) to short summaries [46,50,53]. The booklet length was unclear in four studies [41,44,51,55]. Four interventions 
which included booklets also contained an additional intervention component [41,42,48,51]. A short vignette of 
information was read aloud in one intervention but was not handed to patients in the form of a booklet or leaflet [45].  
Multicomponent educational programmes were utilised as an intervention in five studies. Four of these programmes 
were conducted by health professionals [48,49,51,52] and one education programme was conducted by a non-medical 
person [42].  
Intervention content. All, bar two interventions [49,53], provided some form of treatment risk information to patients 
with MS. Interventions also included information about: treatment benefits [36,41,43,45,47–49,53,54], alternative 
DMDs available to patients [42,45,47,48], efficacy studies for DMDs [42,48,52–54], DMD decision-making [41,42,48,54], 
administration of DMDs [51,52,54] and tailored information about DMDs for patients’ disease subtype [41,55]. 
Intervention presentation methods. Many different methods to present information were employed in the 
interventions. Methods which provided numerical information was manipulated by some studies, for instance by 
presenting or giving explanations for absolute risk numbers [41,43,50,53], relative risk numbers [43] and confidence 
intervals [44]. Four studies used graphical formats in the form of either pictograms [41,43,53] or bar graphs to convey 
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treatment information [54]. One study focused on whether the information was framed in a positive or negative manner 
[41].  
Some interventions also provided treatment information using interactive methods, defined as involving patient in the 
intervention process, which includes: questions and answers [42,47,48,51], discussions in person [42,47,48,51], role-
playing [48], recognition cues [45], information presented in short successions [45] and interactive exercises presented 
at the end of interventions [41,42,47,52]. Media and technology was used to present treatment information in two 
studies [36,48,49,54].  
Together, these strategies were designed to optimise understanding of the risks and benefits of DMDs. 
2.3 Intervention outcomes (table 6) 
Understanding of overall treatment information. Four studies looked at understanding of overall treatment 
information with no particular focus on the risks or benefits of treatments. All employed an objective comprehension 
questionnaire to assess understanding, but maximum scores ranged from 6 to 18.  
Despite no significant difference in the understanding of treatment information between a non-clinical control group 
and MS patients without cognitive impairment, both groups were significantly better than cognitively impaired MS 
patients [45]. The control and MS cognitively unimpaired group showed greater understanding following information 
provided in short successions or when recognition cues were provided to aid recall of information, compared to when 
treatment information was provided in an uninterrupted block [45]. A similar trend was observed in the cognitively 
impaired MS group. However, this group also showed a significant improvement in understanding when recognition 
cues were given alongside treatment information provided in short successive steps, in comparison to information 
provided in successive steps alone [45]. In two other studies, a significant increase in understanding of overall treatment 
information was also evident following intervention when compared to both baseline understanding [52] and a control 
group receiving standard information [44]. However, there was no significant improvement on patients’ understanding 
post-intervention when the control group received identical content as the intervention in a non-interactive form [47].  
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To note, studies differed in the content of the intervention, as only two of the four studies provided information about 
real DMDs [47,52]. Further, only some items in the questionnaires used to assess patients’ understanding focused 
specifically on treatment-related information.  
In summary, although there is a trend towards an improvement in understanding of overall treatment information 
following intervention, this cannot be established with studies employing different interventions and comparison 
groups. 
Treatment risk understanding. The understanding of treatment risks in MS patients following intervention was assessed 
by five studies, using real DMD information in four studies [42,48,50,54] and a hypothetical treatment information in 
another [43]. 
Following a short leaflet about risks of taking Mitoxantrone, MS patients showed a significant increase in accurate risk 
understanding of Leukaemia, an adverse risk associated with the medication [50]. This risk was initially underestimated 
by 58% of MS patients [50]. Underestimation of risk persisted in 18% of MS patients following intervention. Improved 
risk understanding was not dependent on demographic factors, disease duration or the available scientific evidence at 
treatment initiation. However, patients with large errors on the Medical Data Interpretation Test (MDIT), which assessed 
the ability to handle probability data, showed an underestimation of Leukaemia risk after reading the leaflet [50]. 
Following an intervention with a 4-hour education programme combined with a 57-page leaflet, understanding of the 
first-line DMD risks significantly improved for patients in the intervention group compared to MS patients in the control 
group [42]. The authors further combined the scores of risk understanding with patient’s attitude towards their current 
DMD, which they termed as the score of being informed. According to this measure, patients in the intervention group 
were significantly better informed than the control group [42]. Similar results were seen with another multi-component 
intervention, consisting of a 2-hour and 4-hour education programme, in addition to a 120-page information brochure 
[48]. In comparison to the control group receiving standard information brochure and a rehabilitation programme, the 
intervention group showed a significant increase in DMD risk understanding at 2 weeks and 6 months post-intervention 
[48]. 
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One study measured risk understanding using self-report questions after trialling a DMD informational website for 
interferons [54]. Over 80% of MS patients stated that they found the presented risk information really or extremely clear 
and easy to understand [54].  
Using hypothetical treatment information, Kasper and colleagues [43] showed that the ability to recall treatment risks 
from pictograms to frequencies was generally low. However the authors noted that risks were recalled more accurately 
than benefits [43]. Mean errors in recalling risks from pictograms which displayed figures consecutively were 
significantly lower as opposed to pictographs with random arrangement of figures [43]. Patients that attributed high 
personal risk of becoming wheelchair dependent within two years showed a small correlation with overestimation of 
risk following intervention [43].  
Overall, understanding of treatment risks showed an improvement of reasonable accuracy post-intervention despite the 
variety of interventions employed across the reviewed studies, and studies using a mixture of self-report and objective 
measures.  
Treatment benefit understanding. Understanding of treatment benefits was assessed objectively by four studies post-
intervention [43,46,49,53] and with self-report measures by one study [54]. 
Following a 3-page information booklet, MS patients showed significant improvements in understanding of interferon 
benefits post-intervention when compared to baseline [53]. The authors did note that around 99 of 169 patients were 
still not able to understand the information after intervention [53]. Following another educational intervention, there 
was a significant reduction in patients that were overly optimistic about the general benefits of their DMD, even though 
overestimation persisted in about 33% of individuals [49]. At baseline, approximately 34% of MS patients were 
unrealistically optimistic about the benefits of their medication on disease progression specifically. Yet post-
intervention, the number of MS patients overestimating these specific benefits about their DMD increased to about 40% 
[49]. Likewise, in another study, MS patients believed that their medication will provide a greater reduction of risk for a 
maximum walking distance of 100m following the short leaflet-based intervention on Natalizumab, in comparison to 
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physicians [46]. Even with hypothetical treatment information, MS patients overestimated the benefits of a fictitious 
treatment by more than 100% following intervention [43]. 
Using self-report measures, over 75% reported that the interferon benefits presented in a DMD informational website 
were really or extremely clear and that graphical presentations of treatment benefits were easy to understand [54]. 
In summary, initial overestimation of treatment benefits seemingly persists despite interventions that provide treatment 
benefit information beyond routine healthcare, although many patients report their own understanding of treatment 
benefits following intervention as high.  
Personal risk perception. Beyond understanding of treatment risk, two studies also assessed personal perception for 
treatment risks following interventions that provided information about real DMDs [46,50] 
Following a short leaflet about Natalizumab, 84% of MS patients were willing to accept a 1 in 100 or higher risk of PML, 
an adverse side-effect of the medication, compared to only 51% of physicians; showing a significant difference [46]. The 
authors noted that PML risk acceptance was not correlated with understanding of DMD information [46]. Patient’s 
personal risk attribution of PML as an adverse risk of Natalizumab was deemed significantly lower than the PML risk they 
attributed to Natalizumab generally post-intervention [46]. However, since baseline measures were not recorded in the 
study, it is difficult to determine whether personal risk attribution changed as a result of the intervention or was 
previously low at baseline. In another study which did record baseline measures, MS patients showed a significant 
increase from baseline for both general and personal risk attribution of the adverse risks associated with Mitoxantrone 
after reading the informational booklet [50]. Yet similar to the previous study, personal risk attribution of the adverse 
risks of the DMD was significantly lower than general attributed risk of adverse risks by the MS patients [50].  
In summary, two studies show that patients attribute lower personal risks of taking their current DMD than general risks 
they attribute to the DMD, despite improved understanding of their DMD risks post-intervention. 
Treatment decisions. Five studies recorded MS patients’ decision or their attitude for decisions for their current DMD 
following intervention [41,42,46,54,55].  
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Using self-report likert-scales, MS patients in the intervention group were found to be significantly more critical about 
their current DMD compared to baseline and control group, even after four weeks following intervention [41]. Likewise, 
patients were critical towards current DMD after intervention in another study although this attitude did not persist 
beyond two weeks [42]. In another study, patients reported feeling confident in their decision to choose interferons 
after receiving information about interferons beyond routine healthcare [54]. 
MS patients in the intervention group did not show significant differences to the control group in progress of DMD 
decisions during follow-up in two studies [41,42]. When compared with physicians’ decisions however, a considerably 
higher number of patients opted to continue the Natalizumab DMD post-intervention [46]. Although for the same 
medication following another intervention, 60% of MS patients discontinued treatment if they had the highest risk of 
PML, compared to 24% patients with the second-highest PML risk [55]. No patient discontinued the treatment post-
intervention in the lower risk groups [55]. 
In summary, the studies in the present review show a trend towards a critical attitude towards their DMD post-
intervention with some discontinuation due to these attitudes, although the impact on patients’ decisions was generally 
inconclusive in the long-term.  
Intervention feedback. MS patients in six studies provided feedback on the interventions using self-report measures. 
Relative to the control group, MS patients in the intervention group felt better informed and felt that important 
questions had been adequately answered even after six months following intervention [41]. Similarly, MS patients 
deemed the intervention they received as important and felt that this did not increase worries [50]. In fact, 84% of MS 
patients stated that they would recommend the intervention to other patients [50]. Majority of patients reported the 
intervention as useful, and were particularly satisfied with specific training they received during the intervention [51]. 
Likewise, there was a significant increase in patients perception of being informed, in addition to the feeling of certainty 
and confidence of being able to handle all treatments following a DMD information intervention [52]. Over 80% of MS 
patients trialling an informational website reported that the website was easy to navigate, easy to understand and was 
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useful [54]. Following informational materials explaining confidence intervals, patients in the intervention group 
consistently rated the information as being understandable, relevant and beneficial [44]. 
Despite the diversity of the DMD interventions employed in these six studies, self-report measures indicate that patients 
generally perceive any type of interventions as favourable in facilitating understanding of DMD information.  
4. Discussion and Conclusion 
4.1. Discussion 
The present systematic review evaluated 15 interventions designed to improve MS patients’ ability to understand 
complex risk-benefit profiles of DMDs. Studies in the review included MS patients with different clinical subtypes and 
those taking a variety of DMDs. Studies employed a range of outcome measures and not all studies included baseline 
data or control group. Some studies had methodologies that precluded firm conclusions. 
Interventions within the present review provided treatment information using booklets, websites, vignettes and 
education programmes. Half of the interventions included some form of interactive component [41,42,45,47,48,51,52]. 
Yet, there was no apparent advantage of interactive versus passive interventions on understanding. There was also no 
apparent benefit of longer and multicomponent interventions in comparison to shorter and basic interventions such as 
leaflets in the current review. From this, it can be presumed that interventions which are easier to administer and 
require fewer resources may be just as beneficial to employ as longer interventions. Moreover, less than half of the 
interventions manipulated or explained the formats used to present treatment information, such as framing, numerical 
formats or graphical formats [41,43,44,50,53,54]. This is surprising considering that presentation formats are a key 
criteria for an effective evidence-based educational intervention [18] and can significantly impact understanding of 
treatment information [25,26,28,34,35]. Therefore, the use of presentation formats should be carefully considered 
when designing an educational intervention. 
In general, it was difficult to make comparisons between these interventions since they were very diverse in their 
content and administration. In particular, it was not possible to draw conclusions about the most effective intervention 
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which could improve understanding of DMD information in MS patients. However studies that recorded patient’s 
feedback of the interventions all received favourable reviews [41,44,50–52,54], which indicates that any form of 
intervention providing DMD information beyond routine health-care are generally well-accepted by MS patients. 
In terms of the impact of interventions, four interventions improved understanding of overall information provided 
during intervention, despite using very different interventions and study designs [44,45,47,52]. For treatment risk 
knowledge specifically, MS patients initially showed an underestimation of treatment risks during routine healthcare, 
but showed greater understanding of both real and hypothetical treatment risks post-intervention. This improvement in 
risk understanding seemed related to multicomponent interventions [42,48], information which was easier to 
understand [43,50,54] and when personal risk attribution was perceived as low [43]. However, it was not possible to 
determine the extent to which these interventions were able to improve understanding of both adverse risks and side-
effects that are less severe but commonly associated with DMDs. Nevertheless, interventions designed to improve 
understanding of treatment risks could be very beneficial for patients making treatment decisions, since even very small 
changes in the risks of DMDs can have a huge impact on treatment choice [56,57]. In fact, some studies in the present 
review showed a trend towards patients becoming critical or discontinuing treatment when risks were better 
understood [41,43,46,55]. This suggests that patients are likely to review decisions for their current DMD following new 
and enhanced understanding of treatment risks. Considering this, it is important that patients perceive information 
accurately about DMD risks when making initial treatment decisions, so that the true risks associated with their chosen 
treatment are in line with patients’ preferences. Although, some studies in the review showed that despite greater 
understanding of treatments risks, MS patients seemed to underestimate their personal chance of developing these 
risks [46,50]. Interventions in the future could therefore attempt to converge personal risk attribution with accurate 
understanding of treatment risks, to ensure patients are able to apply the knowledge they gain from the intervention 
and make informed treatment decisions based on personal preferences. 
Improvements in understanding the benefits of treatments were less pronounced. Objectively, many patients did not 
understand or tended to overestimate the benefits of taking their treatment, even after receiving additional information 
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[43,46,49,53]. This can be problematic for selecting a course of treatment, as patients are more likely to prematurely 
discontinue treatment if DMD benefits are perceived as higher than actual benefits [49,58]. Such poor adherence to 
DMDs can have both direct and indirect costs for MS patients [59]. However, patients did not significantly change their 
treatment decisions following intervention, similar to the review by Kὅpke and colleagues [36], it is difficult to determine 
the effects of accurate understanding of treatment information on treatment adherence and shared treatment decision-
making. This affirms that understanding of treatment information is simply a precursor to effective shared decision-
making and other key factors such as patient autonomy, patient preferences or decision regret, would also need to be 
addressed in interventions to directly improve shared treatment decision-making [15,60–62]. Such interventions or 
decision aids were present in only three of the 15 included studies in the current review [41,42,48]. 
Additional factors which can likely influence patient’s understanding of DMD information were not fully explored by 
interventions in the present review. Patients’ numeracy and literacy skills have the ability to modify understanding of 
the risks and benefits of treatments, with lower skills often leading to larger number of errors [63–65]. This was only 
explored in one study within the present review, where patients unable to interpret numerical data demonstrated the 
least accuracy in understanding the treatment risk information even after intervention [50]. Aspects of cognitive 
functions affected by MS itself are also likely to influence patient understanding, including: verbal and visual-spatial 
memory [8,66], information-processing speed [5] and decision-making [67,68] . Yet only one interventional study 
monitored cognitive impairments of MS patients in the current review [45]. This study showed that fictitious treatment 
understanding in MS patients with cognitive impairments was considerably lower compared to MS patients who do not 
present these symptoms. However, following additional cueing during intervention, the same level of understanding and 
recall was shown in cognitively impaired MS patients compared with cognitively intact MS patients [45]. Hence, future 
interventions providing treatment information to MS patients may benefit from ensuring that patients of all abilities, 
and those presenting cognitive impairments due to MS, are able to benefit from the additional information given 
beyond routine healthcare.  
  
 
17 
 
A limitation of the present systematic review was the difficulty in drawing robust conclusions or conducting a meta-
analysis for the efficacy of interventions as a result of the different outcome measures employed. A narrative synthesis 
was considered to be the most appropriate format for reviewing the studies. It is important to acknowledge that such a 
qualitative review is subject to greater analysis bias than a quantitative systematic review. 
4.2. Conclusion 
The present review was an inclusive attempt to compare different types of interventions which provide treatment 
information beyond routine healthcare, while evaluating their efficacy on understanding of treatment risks and benefits. 
Despite the heterogeneous findings, it is conceivable to conclude that interventions providing treatment information 
beyond routine healthcare are preferred by MS patients and have the potential to improve understanding of overall 
treatment information, particularly treatment risks. Understanding of treatment benefits do not seem to be reliably 
improved by the reviewed interventions. There was no conclusive effect of interventions on MS patients’ decisions for 
DMDs. No particular intervention type emerged as reliably efficacious. Interventions that were longer and 
comprehensive performed similar to shorter interventions requiring fewer resources. There is a need for a standardised 
information-based tool which can draw on the strengths of currently available interventions and which can improve 
understanding of both the risks and benefits of treatments. 
4.3. Practice implications 
The implication from this review is that MS patients appreciate interventions which provide information about the risks 
and benefits of DMDs beyond routine healthcare. Future interventions need to ensure that effective presentation 
methods are employed to optimise understanding of DMD information during decision-making, and that MS patients of 
all abilities and those presenting cognitive impairments can also benefit from the additional support.  
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Figure 1. PRISMA flow chart for selection process of studies in systematic review 
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Table 1. Search terms for systematic review. 
 
Search terms 
 
(Multiple AND Sclerosis) 
AND 
(patients OR people OR persons OR patient) 
AND 
(risk OR benefit OR side effect OR treatment OR medication OR 
therapy OR medicine OR medical OR therapies OR therapeutics OR 
pharmaceutical preparations) 
AND 
(format OR framing OR educating OR design OR informing OR health 
literacy OR strategy OR program OR intervention OR communicating 
OR information OR education OR learning) 
AND 
(perception OR understanding OR comprehension OR awareness OR 
knowledge OR decision-making) 
 
  
 
Table 2. Quality assessment of studies evaluating interventions to improve patient understanding of DMD information in MS 
 
Overall quality rating: Strong=no weak ratings; Moderate=one weak rating; Weak=two or more weak ratings.  
 
 
 
 
 
 
 
Study (first 
author, year) 
Selection bias Study design Confounders Blinding Data collection 
method 
Withdrawals and 
dropout 
Overall quality 
rating 
Mohr 1996 Moderate Moderate - Moderate Strong Strong Strong 
Kasper 2006 Moderate Moderate Strong Moderate Strong Weak Moderate 
Kasper 2008 Strong Strong Strong Strong Moderate Strong Strong 
Basso 2010 Weak Strong Strong Moderate Strong Moderate Moderate 
Heesen 2010 Moderate Moderate Moderate Weak Moderate - Moderate 
Kasper 2011 Strong Strong Strong Moderate Moderate Strong Strong 
Hofmann 2012 Weak Moderate - Moderate Weak Weak Weak 
Tur 2012 Moderate Weak Strong Moderate Strong Moderate Moderate 
Feicke 2014 Moderate Strong Strong Weak Strong Strong Moderate 
Kӧpke 2014 Strong Strong Strong Strong Strong Strong Strong 
Friedel 2015 Moderate Moderate - Moderate Moderate Weak Moderate 
Zimmer 2015 Moderate Moderate - Moderate Moderate Strong Moderate 
Colombo 2016 Weak Weak - Weak Moderate - Weak 
Kopke 2016 Moderate Strong Strong Moderate Strong Strong Strong 
Rahn 2016 Weak Strong Strong Moderate Strong Weak Weak 
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Table 3. Quality assessment of content and administration of evidence-based patient information: Criteria adapted from Bunge and colleagues (2010) 
 
X = criteria reported; - = criteria unreported or not present 
 
 
 
Study (first 
author, year) 
Numerical 
data (e.g. 
frequencies) 
Graphs (e.g. 
bar chart, 
pictograph) 
Balanced 
framing 
Pictures and 
drawings 
Clear layout 
(e.g. size of 
font) 
Plain language 
and 
readability 
Comprehension 
enhancing tools 
(e.g. mind maps) 
Development process 
(e.g. feedback from 
patients) 
Mohr 1996 x - - - - - - - 
Kasper 2006 x x - - - x - x 
Kasper 2008 x x x - x x - x 
Basso 2010 - - - - - x x - 
Heesen 2010 - - - - - - - - 
Kasper 2011 - x - x - - - - 
Hofmann 2012 x - - - x - - - 
Tur 2012 - - - - - - - x 
Feicke 2014 - - - - - - x x 
Kӧpke 2014 - - - - - - x x 
Friedel 2015 - - - - - - x - 
Zimmer 2015 - - - x - x x - 
Colombo 2016 x x - - x x x x 
Kopke 2016 - - - - - - x x 
Rahn 2016 x - - x - - x x 
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Table 4. Study design and participant demographics 
Study (first 
author, 
year) 
Quality 
ratings 
Methodological 
design 
Recruitment 
method 
Sample size Mean age in 
years 
Type of MS 
(n) 
Disease 
duration and 
time since 
diagnosis 
(years) 
Current DMD 
status 
Real/faux risk-
benefit 
information 
Mohr 1996 Moderate Pre-post 
intervention study 
Outpatient clinics 99 - Not specified - Interferon 
beta-1b 
Real 
Kasper 2006  Pre-post 
intervention study 
Outpatient clinics 169 44 RRMS (75); 
PPMS (75); 
Unclear (19) 
Disease 
duration (7.7) 
DMD (103); 
No DMD (66) 
Real 
Kasper 2008 Strong Double-blind RCT  Newspapers; web-
sites; National self-
help journal 
297 43 CIS (45);  
RRMS (153);  
PPMS (31);  
SPMS (59); 
Unclear (9) 
Time since 
diagnosis: 
IG (8.9) 
CG (8.3) 
Not specified Real 
Basso 2010 Moderate Questionnaire Newspapers; 
Newsletter of MS 
society; MS 
support groups 
36 MS patients 
without cog 
impairments 
(48); 
MS patients with 
cog impairment 
(45); 
CG (38) 
RRMS (14); 
Unclear (22); 
 
- Not specified Real - 
Unrelated to 
DMD 
Heesen 
2010 
Moderate Questionnaire  MS outpatient 
clinics 
69 403 Not specified Disease 
duration (11) 
Natalizumab Real 
Kasper 2011 Strong RCT MS outpatient 
clinic; Centre of 
Neurology; MS 
society 
111 43 Not specified Disease 
duration (7.5) 
Not specified Faux 
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Hofmann 
2012 
Weak Retrospective 
cohort study  
Patients allocated 
Mitoxantrone in 
last 9 years 
(database of 
hospitals and 
private clinics) 
575 50 RRMS (49); 
PPMS (76);  
SPMS (258);  
Other (4);  
Unclear (188)  
Disease 
duration (28.9) 
Mitoxantrone 
(53); 
Terminated 
Mitoxantrone 
(522) 
Real 
Tur 2012 Moderate Survey MS clinics 104 JCV seropositive 
(38); 
JCV seronegative 
(37) 
RRMS Disease 
duration: 
JCV positive 
(13.72) 
JCV negative 
(11.73) 
Natalizumab Real 
Feicke 2014  Quasi-experimental 
study design 
MS clinics; private 
practise 
64 IG (42); 
CG (37) 
RRMS (35); 
PPMS (2);  
SPMS (2);  
Unclear (25) 
Disease 
duration: 
IG (0.97) 
CG (1.64) 
DMD (45); 
No DMD (19) 
Real 
Kopke 2014 Strong Double-blind RCT MS outpatient 
clinics 
192 37 CIS (27); 
RRMS (133); 
Unclear (32) 
Disease 
duration: 
IG (4.3) 
CG = 4.0 
 
Time since 
diagnosis: 
IG (1.4) 
CG (1.2) 
Not specified Real 
Freidal 2015 Moderate Prospective 
longitudinal study 
MS clinics 174 40 RRMS (125); 
Unclear (49) 
Time since 
diagnosis (4.84) 
Interferon-
beta 1b 
 
Previous 
DMD (82); 
No previous 
DMD (75) 
Real 
Zimmer 
2015 
Moderate Pre-post 
intervention study 
MS Centre 98 414 Unclear Time since 
diagnosis (4.64) 
Fingolimod 
 
Previous 
DMD (67); 
Real 
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No previous 
DMD (31) 
Colombo 
2016 
 Survey Press release; 
Website adverts; 
Newsletters; E-
mail invitations; 
Meeting 
presentations 
344 
 
MS patients 
(276) 
Family 
reporting 
about MS 
patients (68) 
MS patients (43); 
Family reporting 
about MS 
patients (45) 
MS patients: 
RRMS (203); 
PPMS (12);  
SPMS (32);  
Unclear (29) 
 
Family 
reporting 
about MS 
patients: 
RRMS (26); 
PPMS (3);  
SPMS (13);  
Unclear (26) 
Disease 
duration: 
MS patients 
(9); 
Family 
reporting 
about MS 
patients (9) 
DMD not 
specified 
Real 
Kopke 2016  Prospective 
controlled trial 
Rehabilitation 
centres 
156 IG (42); 
CG (43) 
CIS (5) 
RRMS (105); 
PPMS (13);  
SPMS (14);  
Unclear (19) 
Time since 
diagnosis: 
IG (7) 
CG (9) 
DMD (88); 
No DMD (68) 
Real 
Rahn 2016  Pilot RCT MS day hospital; 
MS self-help 
society; Other self-
help initiatives 
64 IG (47); 
CG (44) 
CIS (2) 
RRMS (42); 
PPMS (2);  
SPMS (13);  
Unclear (5) 
Disease 
duration: 
IG (9); 
CG (10) 
DMD (29); 
No DMD (35) 
Faux 
Absolute numbers reported, unless specified. Abbreviations: CG, Control group; CIS, clinically isolated syndrome; Cog, Cognitive; DMD, Disease-modifying drug; IG, Intervention 
group; MS, Multiple Sclerosis; PPMS, primary progressive multiple sclerosis; RCT, Randomised controlled trial; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary 
progressive multiple sclerosis. 3=Mode value; 4=Median value 
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Table 5. Outcomes of DMD informational interventions 
Study 
(first 
author, 
year) 
Intervention 
type 
Control 
group 
Intervention 
content 
Intervention 
presentation 
format 
Baseline 
recorded 
Self-report or 
objective 
measure 
Outcome 
measure 
Results 
Mohr 
1996 
Education 
session 
(conducted by 
a MS Nurse) 
None Information about 
treatment benefits 
Videotape Yes Objective DMD benefit 
understanding:  
Survey items 
from BSQ 
(follow up: 
immediate) 
Relapse rate: 
 
Expected <10% reduction (‘overly 
pessimistic group’):  
Baseline = 4% patients;  
Post-intervention = 1% patients 
 
Expected 10-30% reduction (‘accurate 
group’):  
Baseline = 39% patients;  
Post-intervention = 66% patients 
 
Expected >50% reduction (‘overly 
optimistic group’):  
Baseline = 57% patients; 
Post-intervention=33% patients 
 
Disease progression: 
 
Expected no change: Baseline = 40% 
patients; post-intervention = 20% 
 
Expected slower progression: Baseline = 
26% patients; post-intervention = 41% 
 
Expected some restoration of function: 
Baseline = 29% patients; post-
intervention = 37% 
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Expected return to normal function: 
Baseline = 4% patients; post-
intervention = 2% 
 
Kasper 
2006 
3-page 
information 
booklet 
None Interferon DMD 
benefits; 
Clinical trial 
information about 
interferons 
Control event 
rate; 
Experimental 
event rate; 
Absolute risk 
reduction; 
Pictograms 
Yes Objective DMD benefit 
understanding:  
Three items 
(follow up: 
immediate) 
Control event rate: 
 
Pre-intervention = 10% 
Post-intervention = 43% 
Significant difference (p<.001) 
 
Experimental event rate: 
 
Pre-intervention = 33% 
Post-intervention = 43% 
Significant difference (p=.043) 
 
Absolute risk reduction: 
 
Pre-intervention = 21% 
Post-intervention = 41% 
Significant difference (p<.001) 
Kasper 
2008 
120-page new 
Information 
booklet; 
Worksheet 
80-page 
booklet of 
routinely 
available 
information 
Basics of how risks 
are presented; 
Tailored approach 
to disease 
subtype; 
Risk-benefits of 
Probabilities; 
Absolute 
numbers; 
Pictograms of 
risks and 
benefits; 
Yes Self-report Evaluation of 
intervention: 
VAS (follow up: 
>6 months) 
IG = rated value of information higher 
than CG (p<.001) 
IG = better informed than CG (p<.001) 
IG = felt more important questions were 
answered adequately than CG (p<.001) 
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 DMD; 
Decision-making 
Positive and 
negative 
framing; 
Interactive 
exercise 
DMD decisions: 
VAS (follow up: 
baseline, >4 
week, >6 
month) 
Positive attitude of current DMD: 
 
Baseline: CG=62%; IG=65% 
Post-intervention: IG more critical 
towards DMD than CG (>4 week; 
p<0.008) 
 
Progress in decision: 
No sig difference between IG and CG 
Basso 
2010 
Treatment 
disclosure 
vignette (5 
paragraphs of 
2-5 sentences 
each) – read 
aloud to 
people with 
MS 
Treatment -
disclosure 
vignette (5 
paragraphs of 
2-5 sentences 
each) – read 
aloud to 
healthy 
people 
Information about 
treatment; 
Treatment 
benefits and its 
likelihood; 
Treatment risks 
and likelihood; 
Alternative 
treatments and 
their risks-benefits 
1. Information 
read aloud 
uninterrupted; 
2. Information 
read aloud in 
‘chunks’ 
without 
recognition 
cues 
3. Information 
read aloud in 
‘chunks’ with 
recognition 
cues 
No Objective General 
understanding 
of information: 
comprehension 
questions 
(max. 10 
points) (follow 
up: immediate) 
Uninterrupted (mean score): 
CG (n=12): 8.63 
MS-unimpaired (n=24): 7.79 
MS-cog impaired (n=12): 5.58 
 
Information read aloud in ‘chunks’ 
(mean score): 
CG: 9.94 
MS-unimpaired: 8.96 
MS-cog impaired: 8.25 
 
Information read aloud in ‘chunks’ with 
recognition cues (mean score): 
CG: 9.88 
MS-unimpaired: 9.38 
MS-cog impaired: 9.33 
 
CG: Chunking and recognition cueing 
better than uninterrupted (p<.001) 
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MS-unimpaired: Chunking and 
recognition cueing better than 
uninterrupted (p<.001) 
 
MS-cog-impaired: Recognition cueing 
better than chunking and 
uninterrupted; chunking better than 
uninterrupted (p<.001) 
 
Heesen 
2010 
3-page leaflet 3-page leaflet 
given to 
physician’s 
Information about 
natalizumab-
associated PML 
Unclear No Self-report 
 
 
 
 
DMD benefit 
understanding: 
average 
(follow-up: 
immediate) 
 
Risk of maximum walking distance of 
100m after Natalizumab: 
Patients = 40% to 10% 
Physicians = 10% to <10%  
 
10-year risk of being wheelchair-bound 
after Natalizumab: 
Patients = 40% to 10% 
Physicians = 30% to 10% 
 
Progression free after 2 years of 
Natalizumab: 
Patients = 50% 
Physicians = 50% 
Self-report DMD risk 
understanding: 
VAS 
(follow-up: 
immediate) 
Patient’s general PML risk attribution = 
4.5 
No significant difference with physician 
 
Self-report DMD risk 
perception: 4 
risk options 
and VAS 
(follow-up: 
immediate)  
 
Stop Natalizumab at following risk levels 
of PML: 
2:10,000: 
Patients = 17%; Physicians = 49% 
1:100: 
Patients = 29%; Physicians = 48% 
>1:100: 
Patients = 29%; Physicians = 3% 
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Patient’s personal PML risk attribution = 
2.7 
Self-report DMD decisions: 
VAS (0-10) 
(follow-up: 
immediate) 
Willingness to continue treatment 
(mean VAS score): 
 
Patients = 9.0 
Physicians = 6.1 
Kasper 
2011 
Booklet 
 
None Risk-benefit 
profiles of a faux 
DMD: ‘Relevant 
scenario’ (related 
to medication) 
 
Risk-benefit of 
non-medical 
problem: ‘Neutral 
scenario’ (not 
related to 
medication) 
Pictograms 
showing risks-
benefits 
without 
numerical or 
verbal 
explanation; 
Graphical 
explanation of 
absolute and 
relative risk 
reduction; 
No Objective  
 
 
 
DMD risk 
understanding 
of ‘relevant 
scenario’ 
(related to 
medication) 
(follow-up: 
immediate) 
  
 
Mean errors of frequencies of side-
effects: 
 
‘Unsorted pictogram’ group = 15.7% 
(s.d. 12.4) 
‘Sorted pictogram’ group = 10.8% (s.d. 
9.6) 
Total = 11.4%; Mean error = +15.0 
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Graphical 
explanation of 
benefit vs. no-
benefit of DMD 
DMD benefit 
understanding 
of ‘relevant 
scenario’ 
(related to 
medication) 
(follow-up: 
immediate) 
Mean errors of frequencies of benefits: 
 
‘Unsorted pictogram’ group = 20.2% 
(s.d. 20.4) 
‘Sorted pictogram’ group = 16.8% (s.d. 
16.1) 
Total = 16.5%; Mean error = +17.7 
 
 
DMD decisions: 
(follow up: 
immediate) 
No correlation between DMD choice 
and understanding of treatment 
information 
Self-report Evaluation of 
intervention: 
Preference for 
pictograms 
(follow up: 
immediate) 
Preference for ‘unsorted pictograms’ = 
2% 
 
Tur 2012 Booklet None Risk factors of 
PML; Risk of 
discontinuing 
Natalizumab; 
Tailored to 
individual PML risk 
Unclear No Self-report  DMD decisions: 
discontinuation 
of Natalizumab 
treatment 
(follow up: 
immediate)  
Patients with highest PML risk = 60% 
discontinued treatment 
 
Patients with second-highest PML risk = 
24% discontinued treatment 
 
Patients JCV seronegative = 0% 
discontinued treatment 
 
Patients JCV seropositive for less than 2 
years = 0% discontinued treatment 
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Hofmann 
2012 
5-min leaflet None Summary of LK 
and CT risks; 
General risk 
knowledge of 
Mitox 
Absolute risk 
numbers; 
Probability data 
Yes Objective DMS risk 
understanding: 
Risk choice 
from 4 options 
(follow-up: 
immediate) 
 
Risk of Leukemia: 
 
Baseline estimation of risk: 
 
Accurate risk at 8:1000 = 40% 
Underestimation of risk at 8:10,000 = 
58% 
Overestimation of risk = 1% 
 
Post-intervention estimate of risk: 
 
Accurate risk at 8:1000 = 79% 
Underestimation of risk at 8:10,000 = 
18% 
Overestimation of risk = 4% 
 
Self-report DMD risk 
perception: 
General risk 
perception and 
individual risk 
perception 
using VAS 
(follow-up: 
immediate 
Post-intervention: 
 
Significant increase of risk perception 
for Leukemia and cardiotoxicity (p<.05) 
 
Baseline and post-intervention: 
 
General risk perception higher than 
individual risk perception (p<.001). 
 
      Self-report Evaluation of 
intervention: 
VAS rating (0-
10) (follow-up: 
immediate)  
Intervention considered important by 
most patients = 1.1 median VAS rating 
 
Intervention did not increase worries = 
4.7 median VAS rating 
 
Recommend intervention to others = 
85% 
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Feicke 
2014 
420min 
training 
program 
(conducted by 
trained 
neurologist, 
psychologists 
or MS Nurse) 
Brochure 
with same 
content as 
training 
Seven modules 
including:  
Risks and benefits 
of DMDs; 
DMD options;  
General info about 
DMDs 
Discussions; 
Mind maps; 
rating scales; 
interactive 
exercises; Q&A 
Yes Objective General 
understanding 
of information: 
14 
comprehension 
questions 
(follow up: 
baseline, 
immediate, > 6 
month) 
Mean score at baseline: 
CG = 10.70 
IG =10.77 
No significant difference 
 
Mean score post-intervention 
(immediate): 
CG = 11.61 
IG =12.52 
No significant difference 
 
Mean score post-intervention (>6 
months): 
CG = 11.88 
IG =11.77 
No significant difference 
Kopke 
2014 
57-page new 
educational 
booklet ; 
4-hr education 
programme 
(conducted by 
a non-medical 
person) 
 
5 page 
information 
leaflet; 
4-hr 
education 
programme 
for stress 
management 
in MS 
Recent evidence 
of early MS DMD; 
DMD efficacy 
studies; 
DMD options in 
early MS; 
Risks-benefits of 
DMDs in early MS; 
Decision-making 
exercise and 
discussion 
PowerPoint 
presentation; 
Q&A; 
Group 
discussion;  
Guided 
discussion; 
Interactive 
exercises 
Yes Objective DMD risk 
understanding: 
19-item 
questionnaire 
(follow-up: 
baseline; >2 
weeks) 
 
Mean risk knowledge at baseline; 
IG = 10.6 
CG = 9.4 
 
Mean risk knowledge (>2weeks): 
IG = 12.3 
CG = 10.2 
Significant difference (p<.001) 
 
 
 
      Self-report 
 
 
 
 
 
DMD decision-
making: PBMS 
(follow-up: 2 
weeks, 6 and 
12 months) 
IG more critical of DMDs than CG; 
IG felt less social pressure towards DMD 
uptake 
 
DMD status (>6 months) 
IG (n=41): 
Newly initiated DMD = 16 
Discontinued = 5 
 
CG (n=51) 
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Newly initiated DMD = 18 
Discontinued = 12 
Freidal 
2015 
Practical 
education; 
telephone 
consultations; 
home visits; 
(conducted by 
MS Nurses); 
written guide; 
DVD 
None Injection 
techniques; 
management of 
side-effects; 
storage and 
transportation; 
possible side-
effects; 
importance of 
adherence 
Q&A; private 
telephone and 
home 
consultations 
Yes Self-report Evaluation of 
intervention: 6-
point likert 
scale (1=very 
good to 
6=insufficient) 
(follow-up: >3 
months) 
Mean patient ranking: 
Satisfaction with medication application 
(n=114) = 1.11 
Satisfaction with injection training 
(n=111) = 1.23 
Satisfaction with telephonic care (n=58) 
= 1.43 
 
Intervention useful? 
Yes = 64 
Little = 16 
No = 3 
Zimmer 
2015 
60-minute talk 
for treatment-
experienced 
patients; 90-
minute talk for 
newly 
diagnosed 
patients; text 
and picture 
cards; take-
home 
manufacturers 
leaflet 
(conducted by 
MS Nurse) 
None Efficacy and mode 
of action; 
administration, 
pauses and non-
adherence; 
storage; 
pharmacy, costs 
and insurance; 
side-effects and 
how to 
understand 
information 
leaflet; risks and 
prevention; 
monitoring over 
time 
Interactive talk; 
text cards with 
pictures to 
accompany 
talk; ‘memory 
cards’ at end 
with key points 
Yes Objective General 
understanding 
of information: 
questionnaire 
(follow-up: 
immediate) 
Median score (maximum 18): 
Pre-test = 6 
Post-test = 14 
 
 
  
 
40 
 
      Self-report Evaluation of 
intervention: 
VAS (0 = not at 
all informed, to 
10 = totally 
informed) 
(follow-up: 
immediate)  
Perception of being informed: 
 
Pre-intervention: 
Score < 7 = 78; Score > 7 = 19 
Post-intervention: 
Score < 7 = 0; Score > 7 = 97 
 
Certainty of being able to handle all 
treatment: 
 
Pre-intervention: 
Score < 7 = 64; Score > 7 = 33 
Post-intervention: 
Score < 7 = 1; Score > 7 = 96 
 
Confidence in being able to handle all 
treatment aspects: 
 
Pre-intervention: 
Score < 7 = 19; Score > 7 = 78 
Post-intervention: 
Score < 7 = 1; Score > 7 = 96 
Colombo 
2016 
Website None Interferon DMD 
benefits; 
Interferon DMD 
risks; Strength of 
evidence; Areas of 
uncertainty; Long-
term adverse 
effects; Glossary; 
Patient stories; 
Description of 
Short and 
detailed info; 
Bar graphs; 
frequencies; 
verbal info in 
tables 
No Self-report DMD benefit 
understanding 
(follow-up: 
immediate) 
Interferon benefits clear? (n=304) 
No = 6% 
Somewhat = 19% 
Really/extremely = 75% 
 
Graphic presentation of interferon 
benefits easy to understand? (n=304) 
No = 3% 
Somewhat = 18% 
Really/extremely = 79% 
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participant 
characteristics 
from clinical trials; 
Questions to ask 
neurologists; 
Practical 
information about 
interferons 
Self-report DMD risk 
understanding 
(follow-up: 
immediate) 
 
Interferon risks clear? (n=304) 
No = 4% 
Somewhat = 12% 
Really/extremely = 84% 
 
Tables of interferon risks easy to 
understand? (n=304) 
No = 3% 
Somewhat = 12% 
Really/extremely = 85% 
 
Self-report DMD decision-
making 
(follow-up: 
immediate) 
Confident about interferon decision? 
(n=286) 
No = 9% 
Somewhat = 29% 
Really/extremely = 62% 
 
Self-report Evaluation of 
intervention: 
(includes non-
clinical 
intervention 
(n=89)) 
(follow-up: 
immediate) 
Website easy to navigate? (n=418) 
No = 2% 
Somewhat = 5% 
Really/extremely = 93% 
 
Information easy to understand? 
(n=433) 
No = 1% 
Somewhat = 12% 
Really/extremely = 87% 
 
Information useful? (n=433) 
No = 2% 
Somewhat = 14% 
Really/extremely = 84% 
 
Kopke 
2016 
120-page 
information 
brochure; 2-
Printed 
information 
material; 
Information about 
evidence of DMDs; 
Powerpoint 
presentations; 
Yes Objective DMD risk 
understanding 
(follow up: 
Adequate risk knowledge: (> 8 correct 
answers): 
 
  
 
42 
 
hour education 
programme; 4-
hour education 
programme 
(programme 
conducted by 2 
trained MS 
nurses or 
psychologists) 
standard 
rehabilitation 
programme 
Decision-making 
with consultants; 
Risks and benefits 
of new oral 
therapies 
Discussions; 
Q&A; role-play 
baseline, >2 
weeks, >6 
months) 
Baseline: 
CG = 22.5% 
IG = 20.6% 
2-weeks post intervention: 
CG = 31% 
IG = 54.1% 
Significant difference from baseline 
(p<.007) 
6-months post intervention: 
CG = 31.2% 
IG = 48.2% 
Significant difference from 2 weeks 
(p=0.058) 
 
Mean risk knowledge (0-19): 
 
Baseline: 
CG = 6.51 
IG = 6.06 
Non-significant difference (p>.05) 
2-weeks post intervention: 
CG = 7.31 
IG = 8.85 
Significant difference (p<.004) 
6-months post intervention: 
CG = 7.12 
IG = 8.05 
Non-significant difference (p>.05) 
 
Improvement in risk knowledge (>2 
weeks to >6 months): 
CG= 0.59 
IG = 2.52 
Significant difference (p<0.001) 
 
Improvement in risk knowledge 
(baseline to >6 months): 
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CG= 0.46 
IG = 2.12 
Significant difference (p=0002) 
 
Rahn 
2016 
Patient 
information 
materials 
Standard 
information 
Explanation of 
confidence 
intervals, used to 
explain DMD risks 
and benefits 
An example 
story to explain 
confidence 
intervals 
(unrelated to 
MS) 
No Objective General 
understanding 
of information: 
6 questions 
(follow up: 
immediate) 
Mean correct answers: 
CG = 3.8 
IG = 4.8 
Significant difference (p=0.002) 
 
Self-report Evaluation of 
intervention: 
Likert scale (1 = 
not at all, to 10 
= very) 
(follow up: 
immediate) 
Understandable? 
CG = 4.5 
IG = 6.5 
 
Relevant? 
CG = 6.6 
IG = 7.6 
 
Improvement in subjective knowledge? 
CG = 4.8 
IG = 6.6 
Beneficial intervention? 
CG = 6.0 
IG = 7.8 
 
 
Absolute numbers reported, unless specified. Abbreviations: CG, Control group; CIS, clinically isolated syndrome; Cog, Cognitive; CK; Cardiotoxicity; DMD, Disease-modifying 
drug; IG, Intervention group; LK, Leukemia; MDMIC, Multi-Dimensional Measure of Informed Choice; MS, Multiple Sclerosis; PBMS, Planned Behaviour in MS questionnaire; 
PML, progressive multifocal leukoencephalopathy; PPMS, primary progressive multiple sclerosis; Q&A, Questions and answers; RCT, Randomised controlled trial; RRMS, 
relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; VAS, visual analogue scale; UTD, Understanding Treatment Disclosure Scale. 
 
 
 
  
 
 
